ClinicalTrials.gg
CompletedNCT04941755Updated Jan 21, 2022

A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

A Phase 1 interventional study of BMS-986256 and Famotidine in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-21.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the effect of gastric pH changes induced by famotidine on the drug levels of BMS-986256.

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy Participants
  • BMS-986256
  • Famotidine
  • Gastric pH
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants, defined as having no deviations from normal in medical history
  • Weight ≥ 50 kg and between 18.0 kg/m2 and 32.0 kg/m2, inclusive, at screening
  • Normal renal function at screening

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • Current or recent gastrointestinal (GI) disease that could impact upon the absorption of study treatment
  • Any major surgery within 4 weeks of study treatment administration
  • Significant history of GI abnormalities

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Sequence AB

    Drug: BMS-986256 · Drug: Famotidine

  • Experimental
    Sequence BA

    Drug: BMS-986256 · Drug: Famotidine

Interventions

  • Specified dose on specified days

  • Specified dose on specified days

    Also known as: Pepcid

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of BMS-986256

    Time frame: Up to 19 days

  2. Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) of BMS-986256

    Time frame: Up to 19 days

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986256

    Time frame: Up to 19 days

Secondary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: Up to 45 days

  2. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 45 days

  3. Incidence of clinically significant changes in clinical laboratory values: Hematology tests

    Time frame: Up to 45 days

  4. Incidence of clinically significant changes in clinical laboratory values: Chemistry tests

    Time frame: Up to 45 days

  5. Incidence of clinically significant changes in clinical laboratory values: Urinalysis tests

    Time frame: Up to 45 days

  6. Incidence of clinically significant changes in vital signs: Body temperature

    Time frame: Up to 45 days

  7. Incidence of clinically significant changes in vital signs: Respiratory rate

    Time frame: Up to 45 days

  8. Incidence of clinically significant changes in vital signs: Blood pressure

    Time frame: Up to 45 days

  9. Incidence of clinically significant changes in vital signs: Heart rate

    Time frame: Up to 45 days

  10. Incidence of clinically significant changes in Electrocardiogram (ECG) parameters: PR interval

    PR interval is the time from the onset of the P wave to the start of the QRS complex

    Time frame: Up to 45 days

  11. Incidence of clinically significant changes in ECG parameters: QRS

    QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization

    Time frame: Up to 45 days

  12. Incidence of clinically significant changes in ECG parameters: QT interval

    The QT interval is the time from the start of the Q wave to the end of the T wave

    Time frame: Up to 45 days

  13. Incidence of clinically significant changes in ECG parameters: QTcF

    QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave

    Time frame: Up to 45 days

  14. Ratio of Cmax of BMS-986256 (with famotidine versus without famotidine)

    Time frame: Up to 45 days

  15. Ratio of AUC(0-T) of BMS-986256 (with famotidine versus without famotidine)

    Time frame: Up to 45 days

  16. Ratio of AUC(INF) of BMS-986256 (with famotidine versus without famotidine)

    Time frame: Up to 45 days

  17. Time of maximum observed plasma concentration (Tmax) of BMS-986256

    Time frame: Up to 45 days

  18. Apparent terminal plasma half-life (T-HALF) of BMS-986256

    Time frame: Up to 45 days

  19. Apparent total body clearance (CLT/F) of BMS-986256

    Time frame: Up to 45 days

  20. Apparent volume of distribution of terminal phase (Vz/F) of BMS-986256

    Time frame: Up to 45 days

07

Study locations

1 site
  • PPD Development, LP
    Austin, Texas 78744, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Sep 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2021
First posted
Jun 28, 2021
StartActual
Jun 25, 2021
Primary completionActual
Sep 24, 2021
CompletionActual
Sep 24, 2021
Last update
Jan 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04941755
Responsible party
Sponsor
First posted
Jun 28, 2021
Start date
Jun 25, 2021
Primary completion
Sep 24, 2021
Completion
Sep 24, 2021
Last update
Jan 21, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimetoran

Start the discussion